期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

地特胰岛素在2型糖尿病中的应用 被引量：4

Application of Insulin Detemir in Patients with Type 2 Diabetes Mellitus
原文传递
导出
摘要 地特胰岛素是一种新型的基础胰岛素类似物,其入血后可形成独特的双六聚体-白蛋白复合物,发挥长效降糖作用。地特胰岛素疗效可靠,并具有低血糖发生率低、个体内变异性小、体重增加少等临床特点,而体重增加少更是其独特的优势。多项临床研究表明,"基础+口服药"治疗(BOT)方案中每天1次使用地特胰岛素能够达到有效控制血糖的目标。采用303算法或者医生指导调节胰岛素用量可获得同样的效果。 Insulin detemir is a new basal insulin analogue,which could form the dual hexamer-albumin complex in the blood to have a prolonged hypoglycemic effect.Its clinical efficacy is quite satisfactory,with low incidence of hypoglycemia,low within-subject variability in blood glucose concentration,less weight gain and other clinical features,and less weight gain is the unique advantage.A number of trials have shown that BOT（＂basal ＋ oral＂ therapy） with once-daily detemir achieved effective control of blood glucose.To adjust the dose of insulin,there is no significant difference between 303 algorithm and doctor＇s guidance.
作者 于佩 孟振兴 周赛君 于德民
机构地区 天津医科大学代谢病医院糖尿病肾病血液透析科卫生部激素与发育重点实验室
出处 《临床药物治疗杂志》 2013年第1期19-23,共5页 Clinical Medication Journal
关键词 地特胰岛素 2型糖尿病 临床疗效 临床应用 不良反应 insulin detemir type 2 diabetes mellitus efficacy application adverse reactions
分类号 R977.15 [医药卫生—药品] R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献27

  • 1Roach P. New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations [ J ]. Clin Pharmacokinet, 2008, 47(9):595-610.
  • 2L u ddeke HJ, Sreenan S, Aczel S, et al. PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort [ J ]. Diabetes Obes Metab, 2007, 9 (3): 428-434.
  • 3Dornhorst A, Liiddeke H J, Sreenan S, et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort [ J ]. Int J Clin Praet, 2008, 61(3): 523-528.
  • 4Meneghini LF, Dornhorst A, Sreenan S, et al. Once-daily insulin detemir in a cohort of insulin-naive patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study [ J ]. Curr Med Res Opin, 2009, 25(4): 1029-1035.
  • 5Perriello G, Caputo S, De Pergola G, et al. Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects[J]. Expert Opin Pharmacother, 2011, 12(16):2449-2455.
  • 6Khunti K, Caputo S, Damci T, et al. The safety and efficacy of adding once- daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in ten countries [ J ] . Diabetes Obes Metab, 2012, 25 JUL. [ Epub ahead of print ].
  • 7周泽华,肖蓉.地特胰岛素用于治疗口服降糖药控制不佳的2型糖尿病患者疗效观察[J].中国糖尿病杂志,2011,19(5):340-341. 被引量：12
  • 8刘美云.初诊2型糖尿病患者应用地特胰岛素临床研究[J].实用糖尿病杂志,2012,8(2):29-31. 被引量：2
  • 9Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes [J].Diabetes Care, 2006, 29 (6): 1269-1274.
  • 10Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of Once- Daily Insulin Detemir with NPH Insulin Added to a Regimen of Oral Antidiabetic Drags in Poorly Controlled Type 2 Diabetes [ J ]. Clin Therap, 2006, 28(10): 1569-1581.

二级参考文献29

  • 1陆菊明.地特胰岛素的临床实践:PREDICTIVE研究结果分析[J].中华糖尿病杂志,2010,2(1). 被引量：5
  • 2Klein O,Lynge J,Endahl L.Albumin-bound basal insulin analogues (insulin detemir and NN344):comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.Diabet Obes Metab,2007,9:290-299.
  • 3Plank J,Bodenlenz M,Sinner F.A double-blind,randomized,dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.Diabetes Care,2005,28:1107-1112.
  • 4Hermansen K,Daviesm M,Dereznski T,et al.A 26-week,randomized,parallel,treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-na? ve people with type 2 diabetes.Diabetes Care,2006,29:1269-1274.
  • 5Havelund S,Plum A,Ribel U,et al.The mechanism of protraction of insulin detemir,a long-acting,acylated analog of human insulin.Pharm Res,2004,8:1498-1504.
  • 6Dornhorst A,Luddeke HJ,Koenem C,et al.Transferring to insulin detemir from NPH insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycemic control and reduces weight gain and risk of hy-pogly laemia:14 week follow-up from PREDICTIVE.Diabet Obes Metab,2008,10:75-89.
  • 7Heise T, Eckers U, Kane K, et al. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study. Diabetes Teehnol Ther, 2008,10: 479-485.
  • 8Heise T,Nosek L, Ronn RR. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes, 2004, 53: 1614-1620.
  • 9Plank J, Bodendenz M, Sinner E. A double-blind, Vandomized dose-response study investigating the pharmacodynamic and pharmacoknetic properties of long acting insulin analog tier- emir. Diabetes Care, 2005,28 : 1107-1112.
  • 10Kjeld H, Melanie D, Taudeusz D, etal. A 26 week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with tpye 2 diabetes. Diabetes Care, 2006,29 : 1269-1274.

共引文献49

同被引文献33

引证文献4

二级引证文献14

临床药物治疗杂志
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部